Synthesis and Receptor Binding Studies of α5 GABA

Animals Humans Receptors, GABA-A / metabolism Ligands GABA-A Receptor Agonists / pharmacology Benzodiazepines / pharmacology Cognitive Dysfunction / drug therapy gamma-Aminobutyric Acid / metabolism
PDSP cognitive disorders imidazodiazepine off-target profile positive allosteric modulator γ-Aminobutyric acid (GABA)

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
14 Jun 2023
Historique:
received: 24 04 2023
revised: 09 06 2023
accepted: 12 06 2023
medline: 29 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

GABA mediates inhibitory actions through various GABA

Identifiants

DOI: 10.3390/molecules28124771 PMID: 37375326 PMC: PMC10303271
pubmed: 37375326
pii: molecules28124771
doi: 10.3390/molecules28124771
pmc: PMC10303271
pii:
doi:

Substances chimiques

Receptors, GABA-A 0
Ligands 0
GABA-A Receptor Agonists 0
Benzodiazepines 12794-10-4
gamma-Aminobutyric Acid 56-12-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAAA NIH HHS
ID : R01 AA029023
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA043204
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA054177
Pays : United States

Références

J Neurosci. 2019 Jan 30;39(5):788-801
pubmed: 30523065
Biol Psychiatry. 1983 Feb;18(2):185-94
pubmed: 6403063
Biol Psychiatry. 1995 Jun 1;37(11):806-10
pubmed: 7647165
Schizophr Res. 2002 May 1;55(1-2):1-10
pubmed: 11955958
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10164-9
pubmed: 17553960
Am J Med Genet. 1998 Feb 7;81(1):73-80
pubmed: 9514592
Curr Drug Targets. 2015;16(7):735-46
pubmed: 25751008
J Med Chem. 2000 Dec 28;43(26):4927-9
pubmed: 11150162
Cereb Cortex. 2021 Jan 5;31(2):1395-1408
pubmed: 33068001
Brain Res. 1999 Mar 20;822(1-2):265-70
pubmed: 10082908
Neuropharmacology. 2009 Jan;56(1):141-8
pubmed: 18760291
Neural Plast. 2016;2016:2701526
pubmed: 27630777
Biol Psychiatry. 2017 Oct 15;82(8):549-559
pubmed: 28697889
J Affect Disord. 1984 Apr;6(2):131-8
pubmed: 6233345
Psychopharmacol Bull. 1990;26(2):157-61
pubmed: 2236451
Neuropsychopharmacology. 1993 Sep;9(2):125-32
pubmed: 8216695
Biol Psychiatry Glob Open Sci. 2022 Jan 14;3(1):78-86
pubmed: 36712569
Front Cell Neurosci. 2019 Mar 12;13:87
pubmed: 30914923
PNAS Nexus. 2023 Apr 11;2(4):pgad065
pubmed: 37056471
Molecules. 2020 Aug 25;25(17):
pubmed: 32854311
J Affect Disord. 1981 Dec;3(4):339-43
pubmed: 6459350
JAMA Psychiatry. 2014 Jan;71(1):91-3
pubmed: 24196284
Curr Top Med Chem. 2002 Aug;2(8):795-816
pubmed: 12171572
Chem Rev. 1996 Dec 19;96(8):3147-3176
pubmed: 11848856
J Med Chem. 1991 Sep;34(9):2726-35
pubmed: 1895293
Curr Pharm Des. 2014;20(31):5069-76
pubmed: 24345268
J Org Chem. 2002 Sep 6;67(18):6461-73
pubmed: 12201768
Schizophr Bull. 2014 Mar;40(2):341-50
pubmed: 24464874
J Med Chem. 2012 Mar 8;55(5):1817-30
pubmed: 22185670
Neuroscience. 2013 Apr 16;236:345-72
pubmed: 23337532
Br J Pharmacol. 2017 Oct;174(19):3211-3225
pubmed: 28477384
Int J Dev Neurosci. 2017 Oct;61:31-39
pubmed: 28610974
Neuropsychopharmacology. 2011 Aug;36(9):1903-11
pubmed: 21562483
J Neurosci. 2002 Jul 1;22(13):5572-80
pubmed: 12097508
J Comp Neurol. 1995 Aug 14;359(1):154-94
pubmed: 8557845
Mol Psychiatry. 2017 Oct;22(10):1492-1501
pubmed: 27480492
J Neurosci. 2013 Feb 27;33(9):3953-66
pubmed: 23447605
Arch Gen Psychiatry. 2007 Feb;64(2):193-200
pubmed: 17283286
Pharmacol Ther. 2012 Nov;136(2):142-52
pubmed: 22921455
Am J Psychiatry. 2002 Apr;159(4):663-5
pubmed: 11925309
J Med Chem. 2006 Nov 16;49(23):6716-25
pubmed: 17154502
Arch Gen Psychiatry. 2004 Jul;61(7):705-13
pubmed: 15237082
Chem Rev. 2007 Nov;107(11):5210-78
pubmed: 17867708
Ochsner J. 2013 Summer;13(2):214-23
pubmed: 23789008
Mol Psychiatry. 2005 Feb;10(2):201-7
pubmed: 15263904
J Med Chem. 2004 Nov 18;47(24):5829-32
pubmed: 15537339
Pharmacol Rev. 2013 Sep 27;65(4):1257-317
pubmed: 24076545
Front Pharmacol. 2016 Nov 22;7:446
pubmed: 27920723
Org Process Res Dev. 2020 Aug 21;24(8):1467-1476
pubmed: 32952391
J Biol Chem. 2004 Oct 1;279(40):41422-35
pubmed: 15258161
J Biol Chem. 2004 Mar 12;279(11):10120-7
pubmed: 14699101
Autism Res. 2022 May;15(5):806-820
pubmed: 35266641
Cold Spring Harb Perspect Biol. 2011 Aug 01;3(8):a003947
pubmed: 21746798
Org Lett. 2008 Jul 3;10(13):2645-8
pubmed: 18512929
Neuropsychopharmacology. 2012 May;37(6):1548-57
pubmed: 22318195
Bioorg Med Chem Lett. 2008 Jan 1;18(1):215-9
pubmed: 17988864
Pharmacol Rev. 1995 Jun;47(2):181-234
pubmed: 7568326
Biol Psychiatry. 2012 Nov 1;72(9):712-3
pubmed: 23036505
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8980-5
pubmed: 12084936
Bioorg Med Chem. 2008 Jul 15;16(14):6867-72
pubmed: 18550375
Mol Neuropsychiatry. 2019 Apr;5(2):84-97
pubmed: 31192221
Ann Med. 1997 Aug;29(4):275-82
pubmed: 9375983
Arch Gen Psychiatry. 1999 Nov;56(11):1043-7
pubmed: 10565505
Bioorg Med Chem Lett. 2008 Dec 1;18(23):6171-4
pubmed: 18951019
Biol Psychiatry. 1992 Aug 15;32(4):354-63
pubmed: 1420649
Biol Psychiatry. 2009 May 1;65(9):792-800
pubmed: 19058788
Int J Neuropsychopharmacol. 2008 Mar;11(2):255-60
pubmed: 17625025
Neuropharmacology. 2013 Jan;64:145-52
pubmed: 22732440
Neurochem Int. 2002 May;40(6):475-86
pubmed: 11850104
Neurotox Res. 2008 Oct;14(2-3):97-104
pubmed: 19073417
Arch Gen Psychiatry. 2001 Jun;58(6):556-61
pubmed: 11386984
Neuroscience. 2000;101(4):815-50
pubmed: 11113332

Auteurs

Dishary Sharmin (D)

Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin Milwaukee, Milwaukee, WI 53201, USA.

Md Yeunus Mian (MY)

Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin Milwaukee, Milwaukee, WI 53201, USA.

Michael Marcotte (M)

Campbell Family Mental Health Research Institute of CAMH, Toronto, ON M5S 2S1, Canada.

Thomas D Prevot (TD)

Campbell Family Mental Health Research Institute of CAMH, Toronto, ON M5S 2S1, Canada.
Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada.
ORCID: 0000-0002-6774-603X

Etienne Sibille (E)

Campbell Family Mental Health Research Institute of CAMH, Toronto, ON M5S 2S1, Canada.
Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada.
Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5T 1R8, Canada.

Jeffrey M Witkin (JM)

Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin Milwaukee, Milwaukee, WI 53201, USA.
Laboratory of Antiepileptic Drug Discovery, Ascension, St. Vincent, Indianapolis, IN 46260, USA.

James M Cook (JM)

Department of Chemistry and Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin Milwaukee, Milwaukee, WI 53201, USA.
ORCID: 0000-0001-5512-3022

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Synthesis and Receptor Binding Studies of α5 GABA
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Synthesis and Receptor Binding Studies of α5 GABA
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs aux acides aminés › Récepteurs GABA › Récepteurs GABA-A › Synthesis and Receptor Binding Studies of α5 GABA
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Ligands › Synthesis and Receptor Binding Studies of α5 GABA
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents GABA › Agonistes GABA › Agonistes du récepteur GABA-A › Synthesis and Receptor Binding Studies of α5 GABA
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzazépines › Benzodiazépines › Synthesis and Receptor Binding Studies of α5 GABA
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Synthesis and Receptor Binding Studies of α5 GABA
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Amino-butyrates › Acide gamma-amino-butyrique › Synthesis and Receptor Binding Studies of α5 GABA